Post hoc analysis of 1733 young adults with newly diagnosed AML: FLT3-ITD microclones (allelic ratio 0.0004–0.05), seen in 17.4% without macroclones, were independently associated with higher relapse risk (HR 1.50); 2-year relapse 45.1% vs 29.4% without FLT3-ITD.
Secondary analysisn = 1,733
Duployez et al. Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapy